COMPANY
Neuroene Therapeutics
Neuroene Therapeutics’ portfolio includes issued and pending patents covering hundreds of analogs aimed at the treatment of numerous disease indications and the corresponding methods. Neuroene Therapeutics is developing histone deacetylase (HDAC) inhibitors for treating heart failure induced by myocardial ischemia. From company website Source · Oct 13, 2026
NIH awards 6
- NIH award 5R43AI176434-02 FY2024: $299,713 awarded for that fiscal year; activity R43 (SBIR); PI CHAN, SHERINE S; recipient as written: NEUROENE THERAPEUTICS INC, Kensington, MD. A Vitamin K analog countermeasure for source ↗
- NIH award 1R43AI176434-01 FY2023: $298,297 awarded for that fiscal year; activity R43 (SBIR); PI CHAN, SHERINE S; recipient as written: NEUROENE THERAPEUTICS INC, Kensington, MD. A Vitamin K analog countermeasure for source ↗
- NIH award 3R44NS097047-03S1 FY2019: $61,530 awarded for that fiscal year; activity R44 (SBIR); PI CHAN, SHERINE S; recipient as written: NEUROENE THERAPEUTICS INC, Kensington, MD. Administrative Supplement to Promote source ↗
- NIH award 5R44NS097047-03 FY2019: $749,959 awarded for that fiscal year; activity R44 (SBIR); PI CHAN, SHERINE S; recipient as written: NEUROENE THERAPEUTICS INC, Kensington, MD. Development of new anti-epilepsy trea source ↗
- NIH award 2R44NS097047-02 FY2018: $749,959 awarded for that fiscal year; activity R44 (SBIR); PI CHAN, SHERINE S; recipient as written: NEUROENE THERAPEUTICS INC, Kensington, MD. Development of new anti-epilepsy trea source ↗
- NIH award 1R41NS097047-01 FY2016: $224,804 awarded for that fiscal year; activity R41 (STTR); PI CHAN, SHERINE S; recipient as written: NEUROENE THERAPEUTICS INC, Kensington, MD. Novel mechanism for the treatment of source ↗